Ian Scott i.scott@keele.ac.uk
A randomised trial evaluating anakinra in early active rheumatoid arthritis.
Scott, Ian C; Ibrahim, Fowzia; Simpson, Gemma; Kowalczyk, Anna; White-Alao, Beverley; Hassell, Andrew; Plant, Michael; Richards, Selwyn; Walker, David; Scott, David L
Authors
Fowzia Ibrahim
Gemma Simpson
Anna Kowalczyk
Beverley White-Alao
Andrew Hassell a.hassell@keele.ac.uk
Michael Plant
Selwyn Richards
David Walker
David L Scott
Abstract
OBJECTIVES:
The effectiveness of anakinra (interleukin-1 receptor antagonist) in early rheumatoid arthritis (RA) is unknown. We evaluated the efficacy of anakinra (combined with methotrexate) in a randomised clinical trial of early active RA patients.
METHODS:
The Combination Anti-Rheumatic Drugs in Early RA-2 (CARDERA-2) trial was a randomised trial of early (duration <1 year) active RA. Patients were randomised to 12 months of: (1) methotrexate or (2) anakinra-methotrexate. Follow-up lasted 2 years. The primary outcome was erosive progression (changes from baseline in modified Larsen scores). Secondary outcomes were changes from baseline in disease activity score on a 28-joint count (DAS28), health assessment questionnaire (HAQ), and quality of life (EQ-5D) scores alongside ACR responder rates.
RESULTS:
154 patients received the allocated intervention (from 259 screened). Similar Larsen score progression was seen at 12 and 24 months in patients receiving anakinra-methotrexate (mean changes from baseline of 2.50 and 5.10, respectively) and methotrexate monotherapy (mean changes from baseline of 4.16 and 5.20, respectively). Lower improvements in DAS28 and HAQ scores were seen at all time-points in anakinra-methotrexate treated patients; these were significantly less at 24 months (DAS28 p=0.04; HAQ P=0.02). Significantly lower EQ-5D score increases were seen at 12 months with anakinra-methotrexate (p=0.03). Anakinra-methotrexate was associated with more serious adverse events compared with methotrexate monotherapy (11 vs. 6 patients), although this was not significant (p=0.59).
CONCLUSIONS:
Anakinra (combined with methotrexate) is not effective in early, active RA. It provided no clinical benefits beyond methotrexate monotherapy.
Citation
Scott, I. C., Ibrahim, F., Simpson, G., Kowalczyk, A., White-Alao, B., Hassell, A., Plant, M., Richards, S., Walker, D., & Scott, D. L. (2016). A randomised trial evaluating anakinra in early active rheumatoid arthritis. Clinical and Experimental Rheumatology, 34(1), 88-93
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 2, 2015 |
Online Publication Date | Feb 10, 2016 |
Publication Date | 2016 |
Deposit Date | Mar 6, 2024 |
Journal | Clinical and Experimental Rheumatology |
Print ISSN | 0392-856X |
Electronic ISSN | 1593-098X |
Publisher | Springer Vienna |
Peer Reviewed | Peer Reviewed |
Volume | 34 |
Issue | 1 |
Pages | 88-93 |
Public URL | https://keele-repository.worktribe.com/output/525616 |
Publisher URL | https://www.clinexprheumatol.org/abstract.asp?a=9346 |
PMID | 26842950 |
You might also like
P045 Google Internet Searches Related to Inflammatory Arthritis: an Observational Study Using Google Trends Data
(2024)
Presentation / Conference
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search